Latest Financial Results

Q2 2023
Quarter Ended Jun 30, 2023
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2022
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.

Company Overview
We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.
IR Contacts
Headquarters
CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560
T: (510) 293-8800
F: (510) 293-9090
info@cymabay.com
Investor Relations
LifeSci Advisors, LLC
Hans Vitzthum
T: (617) 430-7578
Hans@LifeSciAdvisors.com